Table 3.

Ratios of doses studied or derived from onabotA:incobotA in clinical studies.

Indication	Author/Publication	Ratio (onabotA:incobotA)
Blepharospasm	Bladen et al., 2020 [132]	1:1
	Juarez et al., 2011 [133]	1:1.2
	Kent et al., 2021 [134]	1:1.37
	Kollewe et al., 2015 [118]	1:1.2
	Roggenkämper et al., 2006 [135]	1:1
	Saad and Gourdeau, 2014 [136]	1:1
Cervical dystonia	Benecke et al., 2005 [137]	1:1
	Dressler et al., 2014 [138]	1:1
	Juarez et al., 2011 [133]	1:1.2
	Kent et al., 2021 [134]	1:1.21
Hemifacial spasm	Bladen et al., 2020 [132]	1:1
	Juarez et al., 2011 [133]	1:1.1
Spasticity	Italian Society of Pharmacology, 2017 [139]; Ferrari et al., 2018 [114]	1:1.5–1:2.5
Glabellar lines	Banegas et al., 2013 [140]	1:1
Blepharospasm	Kollewe et al., 2015 [118]	1:2